Literature DB >> 4043169

A pilot study of high-dose domperidone as an antiemetic in patients treated with cisplatin.

M Tonato, F Roila, A del Favero, G Tognoni, M G Franzosi, S Pampallona.   

Abstract

A dose-finding multicenter study was undertaken to evaluate the antiemetic efficacy of domperidone, an antidopaminergic drug, which has been proposed as a suitable alternative to high-dose metoclopramide in the control of cisplatin-induced nausea and vomiting. Forty-five patients were treated with different increasing high doses of domperidone (30, 60, 120 or 150 mg) administered by i.v. infusion over 20 min every 2 hr for a total of four doses for each patient, starting 30 min before chemotherapy. The number of episodes of emesis, the duration of nausea and vomiting and side-effects were recorded. Results do not suggest any specific difference in protective effect between the regimens tested. Moreover, occurrence of serious side-effects indicated that the safety of high-dose domperidone is doubtful.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043169     DOI: 10.1016/0277-5379(85)90219-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  4 in total

1.  Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Authors:  W D Miner; G J Sanger
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

2.  An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.

Authors:  J Carmichael; P A Philip; C Forfar; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.

Authors:  W D Miner; G J Sanger; D H Turner
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

Review 4.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.